Biopotency and efficacy of a FVIII gene therapy construct in hemophilia A mice

被引：0
|
作者：
Hoellriegl, Werner [1 ]
Weiller, Markus [1 ]
Kopic, Alexandra [1 ]
Gritsch, Herbert [1 ]
Gangadharan, Bagirath [2 ]
Falkner, Falko G. [2 ]
Monahan, Paul E. [3 ]
Rottensteiner, Hanspeter [1 ]
Scheiflinger, Edrich [1 ]
Turecek, Marietta [1 ]
机构：
[1] Baxalta Innovat GmbH, Vienna, Austria
[2] Baxalta Innovat Gmbh, Orth Donau, Vienna, Austria
[3] Baxalta US Inc, Northern Illinois, IL USA
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [1] Pharmacodynamic and safety assessment of a FVIII gene therapy construct in hemophilia A mice
    Hoellriegl, W.
    Weiller, M.
    Kopic, A.
    Gritsch, H.
    Gangadharan, B.
    Falkner, F. G.
    Monahan, P. E.
    Rottensteiner, H.
    Scheiflinger, F.
    Turecek, M.
    HUMAN GENE THERAPY, 2016, 27 (11) : A153 - A153
  • [2] Targeting FVIII expression in endothelial and myeloid cells for hemophilia A gene therapy in mice
    Merlin, S.
    Cannizzo, E. S.
    Borroni, E.
    Bruscaggin, V.
    Valente, G.
    Prat, M.
    Arruda, V. R.
    Follenzi, A.
    HUMAN GENE THERAPY, 2016, 27 (11) : A154 - A154
  • [3] The Impact of Anti-Platelet Antagonists on the Hemostatic Efficacy of Platelet-Specific FVIII Gene Therapy in Hemophilia A Mice
    Yu, Hongyin
    Schroeder, Jocelyn A.
    Mattson, Jeremy G.
    Shi, Qizhen
    MOLECULAR THERAPY, 2024, 32 (04) : 520 - 521
  • [4] Platelet αIIbβ3 Receptor Antagonist Impedes the Hemostatic Efficacy of Platelet-Specific FVIII Gene Therapy in Hemophilia a Mice
    Yu, Hongyin
    Schroeder, Jocelyn A.
    Mattson, Jeremy
    Shi, Qizhen
    BLOOD, 2022, 140 : 2712 - 2712
  • [5] The Impact of GPIba on the Efficacy of Platelet-Targeted FVIII Gene Therapy in Hemophilia a with Pre-Existing Anti-FVIII Immunity
    Chen, Juan
    Schroeder, Jocelyn
    Luo, Xiaofeng
    Montgomery, Robert R.
    Shi, Qizhen
    BLOOD, 2015, 126 (23)
  • [6] Anti-CD3 antibodies induce tolerance to FVIII in Hemophilia A mice after FVIII plasmid-mediated gene therapy
    Peng, Baowei
    Ye, Peiqing
    Rawlings, David J.
    Ochs, Hans D.
    Miao, Carol H.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [7] The impact of GPIb on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity
    Chen, Juan
    Schroeder, Jocelyn A.
    Luo, Xiaofeng
    Montgomery, Robert R.
    Shi, Qizhen
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2019, 17 (03) : 449 - 459
  • [8] Co-Administration Therapy Modulates Immunity to FVIII In Hemophilia A Mice
    Hortelano, Gonzalo
    Wen, Jianping
    Chan, Anthony K. C.
    BLOOD, 2011, 118 (21) : 547 - 548
  • [9] Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice
    Pan, Junliang
    Liu, Tongyao
    Kim, Ji-Yun
    Zhu, Daguang
    Patel, Chandra
    Cui, Zhi-Hua
    Zhang, Xin
    Newgren, James O.
    Reames, Aaron
    Canivel, Dodie
    Jesmok, Gary
    Pierce, Glenn F.
    Sommer, Jurg M.
    Jiang, Haiyan
    BLOOD, 2009, 114 (13) : 2802 - 2811
  • [10] Improved efficacy in gene therapy of hemophilia A using an AAV6 pseudo-typed FVIII vector
    Jiang, HY
    Patarroyo-White, S
    Nagy, D
    Vargas, J
    Scallan, C
    Liu, TY
    Powell, S
    Wright, F
    Couto, L
    MOLECULAR THERAPY, 2003, 7 (05) : S184 - S184
12345